Riesgo aterogénico en el déficit de hormona de crecimiento: una mirada desde la infancia
| Issue | Vol. 2 Núm. 2 (2018): Ciencia y Salud, mayo-agosto |
| DOI | |
| Publicado | may 1, 2018 |
|
Estadísticas |
Departamento de Endocrinología Pediátrica. Instituto Nacional de Endocrinología
Departamento de Endocrinología Pediátrica. Instituto Nacional de Endocrinología
Resumen
La Deficiencia de Hormona de Crecimiento es la forma más común de hipopituitarismo en niños. Desde la infancia se asocia con disminución de la masa magra e incremento de la grasa corporal, perfil desfavorable lipídico y glucémico e insulinoresistencia. Todos estos factores aceleran la aterosclerosis y promueven una elevada morbilidad cardiovascular.
1.Alatzoglou KS, Webb EA, Le Tissier P et al. Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. Endocr Rev. 2014;35:376e432.
2.Wit JM, Oostdijk W, Losekoot M et al. Mechanisms in endocrinology: novel genetic causes of short stature. Eur J Endocrinol. 2016;174:R145e73.
3.Argente J, Flores R, Gutierrez-Arumí A et al. Defective minor spliceosome mRNA processing results in isolated familial growth hormone deficiency. EMBO Mol Med. 2014;6:299e306.
4.Webb EA, AlMutair A, Kelberman D et al. ARNT2 mutation causes hypopituitarism, post-natal microcephaly, visual and renal anomalies. Brain. 2013;136:3096e105.
5.Joustra SD, Heinen CA, Schoenmakers N et al. IGSF1 deficiency: lessons from an extensive case series and recommendations for clinical management. J Clin Endocrinol Metab. 2016;101:1627e36.
6.Gregory LC, Gevers EF, Baker J et al. Structural pituitary abnormalities associated with CHARGE syndrome. J Clin Endocrinol Metab. 2013;98:E737e43.
7.Gaston-Massuet C, McCabe MJ, Scagliotti V et al. Transcription factor 7-like 1 is involved in hypothalamo-pituitary axis development in mice and humans. Proc Natl Acad Sci. 2016;113:E548e57.
8.Lucas-Herald AK, Kinning E, Iida A et al. A case of functional growth hormone deficiency and early growth retardation in a child with IFT172 mutations. J Clin Endocrinol Metab. 2015;100:1221e4.
9.Karaca E, Buyukkaya R, Pehlivan D et al. Whole-exome sequencing identifies homozygous GPR161 mutation in a family with pituitary stalk interruption syndrome. J Clin Endocrinol Metab. 2015;100:E140e7.
10.Bashamboo A, Bignon-Topalovic J, Rouba H et al. A nonsense mutation in the hedgehog receptor CDON associated with pituitary stalk interruption syndrome. J Clin Endocrinol Metab. 2016;101:12e5.
11.Patat O, van Ravenswaaij-Arts CMA, Tantau J et al. Otocephaly-dysgnathia complex: description of four cases and confirmation of the role of OTX2. Mol Syndromol. 2013;4:302e5.
12.Sergouniotis PI, Urquhart JE, Williams SG et al. Agnathia-otocephaly complex and asymmetric velopharyngeal insufficiency due to an in-frame duplication in OTX2. J Hum Genet. 2015;60:199e202.
13.Vincent A, Forster N, Maynes JT et al. OTX2 mutations cause autosomal dominant pattern dystrophy of the retinal pigment epithelium. J Med Genet. 2014;51:797e805.
14.Williamson KA, Fitz Patrick. The genetic architecture of microphthalmia, anophthalmia and coloboma. Eur J Med Genet. 2014;57:369e80.
15.Franca MM, Jorge AAL, Carvalho LRS et al. Novel heterozygous nonsense GLI2 mutations in patients with hypopituitarism and ectopic posterior pituitary lobe without holoprosencephaly. J Clin Endocrinol Metab. 2010;95:E384e91.
16.Demurger F, Ichkou A, Mougou-Zerelli S et al. New insights into genotype-phenotype correlation for GLI3 mutations. Eur J Hum Genet. 2015;23:92e102.
17.Gregory LC, Humayun KN, Turton JP et al. Novel lethal form of congenital hypopituitarism associated with the first recessive LHX4 mutation. J Clin Endocrinol Metab. 2015;100:2158e64.
18.Gregory LC, Gaston-Massuet C, Andoniadou CL et al. The role of the sonic hedgehog signalling pathway in patients with midline defects and congenital hypopituitarism. Clin Endocrinol. 2015;82:728e38.
19.McCabe MJ, Gaston-Massuet C, Tziaferi V et al. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. J Clin Endocrinol Metab. 2011;96:E1709e18.
20.Correa FA, Trarbach EB, Tusset C et al. FGFR1 and PROKR2 rare variants found in patients with combined pituitary hormone deficiencies. Endocr Connect. 2015;4:100e7.
21.Xu H, Niu Y, Wang T et al. Novel FGFR1 and KISS1R mutations in Chinese Kallmann syndrome males with cleft lip/palate. Biomed Res Int. 2015. http://dx.doi. org/10.1155/2015/649698.
22.Asakura Y, Muroya K, Hanakawa J et al. Combined pituitary hormone deficiency with unique pituitary dysplasia and morning glory syndrome related to a heterozygous PROKR2 mutation. Clin Pediatr Endocrinol. 2015;24:27e32.
23.Reynaud R, Jayakody SA, Monnier C et al. PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. J Clin Endocrinol Metab. 2012;97:1068e73.
24.McCabe MJ, Gaston-Massuet C, Gregory LC et al. Variations in PROKR2, but not PROK2, are associated with hypopituitarism and septo-optic dysplasia. J Clin Endocrinol Metab. 2013;98:E547e57.
25.Quentien MH, Delemer B, Papadimitriou DT et al. Deficitin anterior pituitary function and variable immune deficiency (DAVID) in children presentingwith adrenocorticotropin deficiency and severe infections. J Clin Endocrinol Metab. 2012;9:121e8.
26.Takagi M, Nagasaki K, Fujiwara I et al. Heterozygous defects in PAX6 gene and congenital hypopituitarism. Eur J Endocrinol. 2015;172:37e45.
27.Castinetti F, Reynaud R, Saveanu A et al. Mechanisms in endocrinology: an update in the genetic aetiologies of combined pituitary hormone deficiency. Eur J Endocrinol. 2016;174:R239e47.
28.V. Khadilkar, V. Ekbote, N. Kajale, A. Khadilkar, S. Chiplonkar, A. Kinare, Effect of oneyear growth hormone therapy on body composition and cardio-metabolic risk in Indian children with growth hormone deficiency, Endocr. Res. 2014(39)73-78.
29.Prodam F, Savastio S, Genoni G et al. Effects of growth hormone (GH) therapy withdrawal on glucose metabolism in not confirmed GH deficient adolescents at final height. PLoS One. 2014;9(1):e87157.
30.Palmeiro CR, Anand R, Dardi IK, Balasubramaniyam N, Schwarcz MD, Weiss IA. Growth hormone and the cardiovascular system. Cardiol Rev. 2012; 20: 197-207.
31.Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf). 2008 Sep;69(3):347e58.
32.Isgaard J, Arcopinto M, Karason K et al. GH and the cardiovascular system: an update on a topic at heart. Endocrine. 2015 Feb;48(1):25e35.
33.Gazzaruso C, Gola M, Karamouzis I et al. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GHean update. J Clin Endocrinol Metab. 2014 Jan;99(1):18e29.
34.Kuromaru R, Kohno H, Ueyama N et al. Long-term effect of growth hormone (GH) treatment on body composition in children with GH deficiency. Endocr J. 1999 Mar;46(Suppl):S35e8.
35.Lacey KA, Parkin JM. Causes of short stature. A community study of children in Newcastle upon Tyne. Lancet. 1974;12: 42e5.
36.Rona RJ, Tanner JM. Aetiology of idiopathic growth hormone deficiency in England and Wales. Arch Dis Childhood. 1977;52:197e208.
37.Murray PG, Paterson WF, Donaldson MD. Maternal age in patients with septo-optic dysplasia. J Pediatr Endocrinol Metab. 2005;18:471e6.
38.Bao XL, Shi YF, Du YC et al. Prevalence of growth hormone deficiency of children in Beijing. Chin Med J (Engl). 1992;105:401e5.
39.Migliaretti G, Aimaretti G, Borraccino A et al. Incidence and prevalence rate estimation of growth hormone treatment exposure in Piedment paediatric population in the years 2002e2004: data from the GH registry. J Endocrinol Invest. 2006;29:438e42.
40.Alberti KG, Zimmet P, Shaw J. Metabolic syndromeea new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006 May;23(5):469e80.
41.Johansson JO, Landin K, Tengborn L et al. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb. 1994 Mar;14(3):434e7.
42.Jorgensen JO, Pedersen SA, Thuesen L et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1989 Jun 3;1(8649):1221e5.
43.Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptinethe classical, resistinethe controversial, adiponectinethe promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005 Dec;19(4):525e46.
44.Roth CL, Reinehr T. Roles of gastrointestinal and adipose tissue peptides in childhood obesity and changes after weight loss due to lifestyle intervention. Arch Pediatr Adolesc Med. 2010 Feb;164(2):131e8.
45.De Leonibus C, De Marco S, Stevens A et al. Growth hormone deficiency in prepubertal children: predictive markers of cardiovascular disease. Horm Res Paediatr. 2016;85(6):363e71.
46.Jorgensen JO, Vestergaard E, Gormsen L et al. Metabolic consequences of GH deficiency. J Endocrinol Investig. 2005;28(5 Suppl):47e51.
47.LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):302e10.
48.Bramnert M, Segerlantz M, Laurila E et al. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab. 2003 Apr; 88(4):1455e63.
49.Salomon F, Cuneo RC, Hesp R et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989 Dec 28;321(26):1797e803.
50.Appelman-Dijkstra NM, Claessen KM, Roelfsema F et al. Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol. 2013 Jul; 169(1):R1e14.
51.Carroll PV, Drake WM, Maher KT et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab. 2004 Aug;89 (8):3890e5.
52.Salerno M, Esposito V, Farina V et al. Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. J Clin Endocrinol Metab. 2006 Apr;91(4):1288e95.
53.Ciresi A, Ciccio F, Amato MC et al. Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA). J Endocrinol Investig. 2015 Dec;38(12):1301e7.
54.Ramistella V, Wasniewska M, Arasi S et al. Cross-sectional and prospective study of the effects of GH therapy on metabolic panel in children with GH deficiency. Pediatr Med Chir. 2014 Sep;36(5e6):104.
55.Metwalley KA, Farghaly HS, Abd El-Hafeez HA. Evaluation of left ventricular mass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: a single-center prospective case-control study. Indian J Endocrinol Metab. 2013 Sep;17(5):876e82.
56.Meazza C, Elsedfy HH, Pagani S et al. Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res. 2014 Mar;46(3):219e23.
57.Ciresi A, Amato MC, Giordano C. Reduction in insulin sensitivity and inadequate beta-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. J Endocrinol Investig. 2015 Mar;38(3):351e9.
58.Boot AM, Engels MA, Boerma GJ et al. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J Clin Endocrinol Metab. 1997 Aug;82(8):2423e8.
59.Kohno, H, Tanaka, T, Fujieda, K. Chihara, K, Seino, Y, Irie, M, Takano, K. Favorable impacts of growth hormone (GH) replacement therapy on atherogenic risks in Japanese children with GH deficiency, Clin Pediatr Endocrinol. 2012(21):15-20.
60.Capalbo D, Mattace RG, Esposito A et al. Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study. Clin Endocrinol (Oxf). 2014 Jun;80(6):856e62.
61.K.A.Metwalley, H.S. Farghaly, H.A. Abd ElHafeez, Evaluation of left ventricularmass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: a single-center prospective case– control study, Indian J. Endocrinol. Metab. 17 (2013) 876–882.
62.Wollmann HA, Ranke MB. Metabolic effects of growth hormone in children. Metabolism. 1995 Oct;44(10 Suppl 4): 97e102.
63.Melmed S. Idiopathic adult growth hormone deficiency. J Clin Endocrinol Metab. 2013 Jun;98(6):2187e97.
64.Pasarica M, Zachwieja JJ, deJonge L et al. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. J Clin Endocrinol Metab. 2007 Nov;92(11):4265e70.
65.Mokha JS, Srinivasan SR, Dasmahapatra P, Fernandez C, Chen W, Xu J et al. Utility of waist-to-height ratio in assessing the status of central obesity and related cardiometabolic risk profile among normal weight and overweight/obese children: the Bogalusa Heart Study. BMC Pediatr. 2010;10:73.
66.Beauregard C, Utz AL, Schaub AE et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008 Jun;93(6):2063e71.
67.Reinehr T, Lindberg A, Koltowska-Haggstrom M et al. Is growth hormone treatment in children associated with weight gain? e Longitudinal analysis of KIGS data. Clin Endocrinol (Oxf). 2014 Nov;81(5):721e6.
68.Gleeson H, Barreto ES, Salvatori R et al. Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation. Clin Endocrinol (Oxf). 2007 Apr;66(4):466e74.
69.Roth CL, Kratz M, Ralston MM et al. Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children. Metabolism. 2011 Apr;60(4):445e52.
70.Colao A, Di SC, Salerno et al. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab. 2002 Aug; 87(8):3650e5.
71.McGrath S, Morris M, Bouloux PM. Growth hormone deficiency and atherosclerosiseis there a link? Growth Horm IGF Res. 1999 Apr;9(Suppl A):9e13.
72.Hoybye C, Christiansen JS. Growth hormone replacement in adults current standards and new perspectives. Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):115e23.
73.Hallengren E, Almgren P, Engstrom G et al. Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malmo diet and cancer study. J Am Coll Cardiol. 2014 Oct 7;64(14):1452e60.
74.Carel JC, Ecosse E, Landier F et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone
deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012 Feb;97(2):416e25.
75.Savendahl L, Maes M, Albertsson-Wikland K et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012 Feb;97(2):E213e7.
76.Albertsson-Wikland K, Martensson A, Savendahl L et al. Mortality is not increased in rhGH-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab. 2016 Feb 26:(2):539e51.
77. Mo D, Hardin DS, Erfurth EM et al. Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS). Pituitary. 2014 Oct;17(5):477e85.
78. Davis PH, Dawson JD, Riley WA et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001 Dec 4;104(23):2815e9.
79. Reinehr T, Kiess W, de Sousa G et al. Intima media thickness in childhood obesity: relations to inflammatory marker, glucose metabolism, and blood pressure. Metabolism. 2006 Jan;55(1):113e8.
80. Colao A, Di SC, Spiezia S et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab. 2008 Sep;93(9): 3416e24.
81. Capalbo D, Mattace Raso G, Di Mase R et al. Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study. Clin Endocrinol. 2013;80:856-62.
82. Knop C, Wolters B, Lass N et al. Carotid intima-media thickness in children treated with growth hormone. J Pediatr Endocrinol Metab. 2015 Sep;28(9-10):985e91.
2.Wit JM, Oostdijk W, Losekoot M et al. Mechanisms in endocrinology: novel genetic causes of short stature. Eur J Endocrinol. 2016;174:R145e73.
3.Argente J, Flores R, Gutierrez-Arumí A et al. Defective minor spliceosome mRNA processing results in isolated familial growth hormone deficiency. EMBO Mol Med. 2014;6:299e306.
4.Webb EA, AlMutair A, Kelberman D et al. ARNT2 mutation causes hypopituitarism, post-natal microcephaly, visual and renal anomalies. Brain. 2013;136:3096e105.
5.Joustra SD, Heinen CA, Schoenmakers N et al. IGSF1 deficiency: lessons from an extensive case series and recommendations for clinical management. J Clin Endocrinol Metab. 2016;101:1627e36.
6.Gregory LC, Gevers EF, Baker J et al. Structural pituitary abnormalities associated with CHARGE syndrome. J Clin Endocrinol Metab. 2013;98:E737e43.
7.Gaston-Massuet C, McCabe MJ, Scagliotti V et al. Transcription factor 7-like 1 is involved in hypothalamo-pituitary axis development in mice and humans. Proc Natl Acad Sci. 2016;113:E548e57.
8.Lucas-Herald AK, Kinning E, Iida A et al. A case of functional growth hormone deficiency and early growth retardation in a child with IFT172 mutations. J Clin Endocrinol Metab. 2015;100:1221e4.
9.Karaca E, Buyukkaya R, Pehlivan D et al. Whole-exome sequencing identifies homozygous GPR161 mutation in a family with pituitary stalk interruption syndrome. J Clin Endocrinol Metab. 2015;100:E140e7.
10.Bashamboo A, Bignon-Topalovic J, Rouba H et al. A nonsense mutation in the hedgehog receptor CDON associated with pituitary stalk interruption syndrome. J Clin Endocrinol Metab. 2016;101:12e5.
11.Patat O, van Ravenswaaij-Arts CMA, Tantau J et al. Otocephaly-dysgnathia complex: description of four cases and confirmation of the role of OTX2. Mol Syndromol. 2013;4:302e5.
12.Sergouniotis PI, Urquhart JE, Williams SG et al. Agnathia-otocephaly complex and asymmetric velopharyngeal insufficiency due to an in-frame duplication in OTX2. J Hum Genet. 2015;60:199e202.
13.Vincent A, Forster N, Maynes JT et al. OTX2 mutations cause autosomal dominant pattern dystrophy of the retinal pigment epithelium. J Med Genet. 2014;51:797e805.
14.Williamson KA, Fitz Patrick. The genetic architecture of microphthalmia, anophthalmia and coloboma. Eur J Med Genet. 2014;57:369e80.
15.Franca MM, Jorge AAL, Carvalho LRS et al. Novel heterozygous nonsense GLI2 mutations in patients with hypopituitarism and ectopic posterior pituitary lobe without holoprosencephaly. J Clin Endocrinol Metab. 2010;95:E384e91.
16.Demurger F, Ichkou A, Mougou-Zerelli S et al. New insights into genotype-phenotype correlation for GLI3 mutations. Eur J Hum Genet. 2015;23:92e102.
17.Gregory LC, Humayun KN, Turton JP et al. Novel lethal form of congenital hypopituitarism associated with the first recessive LHX4 mutation. J Clin Endocrinol Metab. 2015;100:2158e64.
18.Gregory LC, Gaston-Massuet C, Andoniadou CL et al. The role of the sonic hedgehog signalling pathway in patients with midline defects and congenital hypopituitarism. Clin Endocrinol. 2015;82:728e38.
19.McCabe MJ, Gaston-Massuet C, Tziaferi V et al. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. J Clin Endocrinol Metab. 2011;96:E1709e18.
20.Correa FA, Trarbach EB, Tusset C et al. FGFR1 and PROKR2 rare variants found in patients with combined pituitary hormone deficiencies. Endocr Connect. 2015;4:100e7.
21.Xu H, Niu Y, Wang T et al. Novel FGFR1 and KISS1R mutations in Chinese Kallmann syndrome males with cleft lip/palate. Biomed Res Int. 2015. http://dx.doi. org/10.1155/2015/649698.
22.Asakura Y, Muroya K, Hanakawa J et al. Combined pituitary hormone deficiency with unique pituitary dysplasia and morning glory syndrome related to a heterozygous PROKR2 mutation. Clin Pediatr Endocrinol. 2015;24:27e32.
23.Reynaud R, Jayakody SA, Monnier C et al. PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. J Clin Endocrinol Metab. 2012;97:1068e73.
24.McCabe MJ, Gaston-Massuet C, Gregory LC et al. Variations in PROKR2, but not PROK2, are associated with hypopituitarism and septo-optic dysplasia. J Clin Endocrinol Metab. 2013;98:E547e57.
25.Quentien MH, Delemer B, Papadimitriou DT et al. Deficitin anterior pituitary function and variable immune deficiency (DAVID) in children presentingwith adrenocorticotropin deficiency and severe infections. J Clin Endocrinol Metab. 2012;9:121e8.
26.Takagi M, Nagasaki K, Fujiwara I et al. Heterozygous defects in PAX6 gene and congenital hypopituitarism. Eur J Endocrinol. 2015;172:37e45.
27.Castinetti F, Reynaud R, Saveanu A et al. Mechanisms in endocrinology: an update in the genetic aetiologies of combined pituitary hormone deficiency. Eur J Endocrinol. 2016;174:R239e47.
28.V. Khadilkar, V. Ekbote, N. Kajale, A. Khadilkar, S. Chiplonkar, A. Kinare, Effect of oneyear growth hormone therapy on body composition and cardio-metabolic risk in Indian children with growth hormone deficiency, Endocr. Res. 2014(39)73-78.
29.Prodam F, Savastio S, Genoni G et al. Effects of growth hormone (GH) therapy withdrawal on glucose metabolism in not confirmed GH deficient adolescents at final height. PLoS One. 2014;9(1):e87157.
30.Palmeiro CR, Anand R, Dardi IK, Balasubramaniyam N, Schwarcz MD, Weiss IA. Growth hormone and the cardiovascular system. Cardiol Rev. 2012; 20: 197-207.
31.Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf). 2008 Sep;69(3):347e58.
32.Isgaard J, Arcopinto M, Karason K et al. GH and the cardiovascular system: an update on a topic at heart. Endocrine. 2015 Feb;48(1):25e35.
33.Gazzaruso C, Gola M, Karamouzis I et al. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GHean update. J Clin Endocrinol Metab. 2014 Jan;99(1):18e29.
34.Kuromaru R, Kohno H, Ueyama N et al. Long-term effect of growth hormone (GH) treatment on body composition in children with GH deficiency. Endocr J. 1999 Mar;46(Suppl):S35e8.
35.Lacey KA, Parkin JM. Causes of short stature. A community study of children in Newcastle upon Tyne. Lancet. 1974;12: 42e5.
36.Rona RJ, Tanner JM. Aetiology of idiopathic growth hormone deficiency in England and Wales. Arch Dis Childhood. 1977;52:197e208.
37.Murray PG, Paterson WF, Donaldson MD. Maternal age in patients with septo-optic dysplasia. J Pediatr Endocrinol Metab. 2005;18:471e6.
38.Bao XL, Shi YF, Du YC et al. Prevalence of growth hormone deficiency of children in Beijing. Chin Med J (Engl). 1992;105:401e5.
39.Migliaretti G, Aimaretti G, Borraccino A et al. Incidence and prevalence rate estimation of growth hormone treatment exposure in Piedment paediatric population in the years 2002e2004: data from the GH registry. J Endocrinol Invest. 2006;29:438e42.
40.Alberti KG, Zimmet P, Shaw J. Metabolic syndromeea new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006 May;23(5):469e80.
41.Johansson JO, Landin K, Tengborn L et al. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb. 1994 Mar;14(3):434e7.
42.Jorgensen JO, Pedersen SA, Thuesen L et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1989 Jun 3;1(8649):1221e5.
43.Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptinethe classical, resistinethe controversial, adiponectinethe promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005 Dec;19(4):525e46.
44.Roth CL, Reinehr T. Roles of gastrointestinal and adipose tissue peptides in childhood obesity and changes after weight loss due to lifestyle intervention. Arch Pediatr Adolesc Med. 2010 Feb;164(2):131e8.
45.De Leonibus C, De Marco S, Stevens A et al. Growth hormone deficiency in prepubertal children: predictive markers of cardiovascular disease. Horm Res Paediatr. 2016;85(6):363e71.
46.Jorgensen JO, Vestergaard E, Gormsen L et al. Metabolic consequences of GH deficiency. J Endocrinol Investig. 2005;28(5 Suppl):47e51.
47.LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):302e10.
48.Bramnert M, Segerlantz M, Laurila E et al. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab. 2003 Apr; 88(4):1455e63.
49.Salomon F, Cuneo RC, Hesp R et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989 Dec 28;321(26):1797e803.
50.Appelman-Dijkstra NM, Claessen KM, Roelfsema F et al. Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol. 2013 Jul; 169(1):R1e14.
51.Carroll PV, Drake WM, Maher KT et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab. 2004 Aug;89 (8):3890e5.
52.Salerno M, Esposito V, Farina V et al. Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. J Clin Endocrinol Metab. 2006 Apr;91(4):1288e95.
53.Ciresi A, Ciccio F, Amato MC et al. Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA). J Endocrinol Investig. 2015 Dec;38(12):1301e7.
54.Ramistella V, Wasniewska M, Arasi S et al. Cross-sectional and prospective study of the effects of GH therapy on metabolic panel in children with GH deficiency. Pediatr Med Chir. 2014 Sep;36(5e6):104.
55.Metwalley KA, Farghaly HS, Abd El-Hafeez HA. Evaluation of left ventricular mass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: a single-center prospective case-control study. Indian J Endocrinol Metab. 2013 Sep;17(5):876e82.
56.Meazza C, Elsedfy HH, Pagani S et al. Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res. 2014 Mar;46(3):219e23.
57.Ciresi A, Amato MC, Giordano C. Reduction in insulin sensitivity and inadequate beta-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. J Endocrinol Investig. 2015 Mar;38(3):351e9.
58.Boot AM, Engels MA, Boerma GJ et al. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J Clin Endocrinol Metab. 1997 Aug;82(8):2423e8.
59.Kohno, H, Tanaka, T, Fujieda, K. Chihara, K, Seino, Y, Irie, M, Takano, K. Favorable impacts of growth hormone (GH) replacement therapy on atherogenic risks in Japanese children with GH deficiency, Clin Pediatr Endocrinol. 2012(21):15-20.
60.Capalbo D, Mattace RG, Esposito A et al. Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study. Clin Endocrinol (Oxf). 2014 Jun;80(6):856e62.
61.K.A.Metwalley, H.S. Farghaly, H.A. Abd ElHafeez, Evaluation of left ventricularmass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: a single-center prospective case– control study, Indian J. Endocrinol. Metab. 17 (2013) 876–882.
62.Wollmann HA, Ranke MB. Metabolic effects of growth hormone in children. Metabolism. 1995 Oct;44(10 Suppl 4): 97e102.
63.Melmed S. Idiopathic adult growth hormone deficiency. J Clin Endocrinol Metab. 2013 Jun;98(6):2187e97.
64.Pasarica M, Zachwieja JJ, deJonge L et al. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. J Clin Endocrinol Metab. 2007 Nov;92(11):4265e70.
65.Mokha JS, Srinivasan SR, Dasmahapatra P, Fernandez C, Chen W, Xu J et al. Utility of waist-to-height ratio in assessing the status of central obesity and related cardiometabolic risk profile among normal weight and overweight/obese children: the Bogalusa Heart Study. BMC Pediatr. 2010;10:73.
66.Beauregard C, Utz AL, Schaub AE et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008 Jun;93(6):2063e71.
67.Reinehr T, Lindberg A, Koltowska-Haggstrom M et al. Is growth hormone treatment in children associated with weight gain? e Longitudinal analysis of KIGS data. Clin Endocrinol (Oxf). 2014 Nov;81(5):721e6.
68.Gleeson H, Barreto ES, Salvatori R et al. Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation. Clin Endocrinol (Oxf). 2007 Apr;66(4):466e74.
69.Roth CL, Kratz M, Ralston MM et al. Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children. Metabolism. 2011 Apr;60(4):445e52.
70.Colao A, Di SC, Salerno et al. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab. 2002 Aug; 87(8):3650e5.
71.McGrath S, Morris M, Bouloux PM. Growth hormone deficiency and atherosclerosiseis there a link? Growth Horm IGF Res. 1999 Apr;9(Suppl A):9e13.
72.Hoybye C, Christiansen JS. Growth hormone replacement in adults current standards and new perspectives. Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):115e23.
73.Hallengren E, Almgren P, Engstrom G et al. Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malmo diet and cancer study. J Am Coll Cardiol. 2014 Oct 7;64(14):1452e60.
74.Carel JC, Ecosse E, Landier F et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone
deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012 Feb;97(2):416e25.
75.Savendahl L, Maes M, Albertsson-Wikland K et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012 Feb;97(2):E213e7.
76.Albertsson-Wikland K, Martensson A, Savendahl L et al. Mortality is not increased in rhGH-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab. 2016 Feb 26:(2):539e51.
77. Mo D, Hardin DS, Erfurth EM et al. Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS). Pituitary. 2014 Oct;17(5):477e85.
78. Davis PH, Dawson JD, Riley WA et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001 Dec 4;104(23):2815e9.
79. Reinehr T, Kiess W, de Sousa G et al. Intima media thickness in childhood obesity: relations to inflammatory marker, glucose metabolism, and blood pressure. Metabolism. 2006 Jan;55(1):113e8.
80. Colao A, Di SC, Spiezia S et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab. 2008 Sep;93(9): 3416e24.
81. Capalbo D, Mattace Raso G, Di Mase R et al. Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study. Clin Endocrinol. 2013;80:856-62.
82. Knop C, Wolters B, Lass N et al. Carotid intima-media thickness in children treated with growth hormone. J Pediatr Endocrinol Metab. 2015 Sep;28(9-10):985e91.
Deficiencia de Hormona de Crecimiento
hipopituitarismo
riesgo aterogénico
- Resumen visto - 619 veces
- PDF descargado - 327 veces
- HTML descargado - 161 veces
Descargas
Los datos de descargas todavía no están disponibles.
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Copyright
© Ciencia y Salud, 2018
Afiliaciones
Francisco Carvajal Martínez
Departamento de Endocrinología Pediátrica. Instituto Nacional de Endocrinología
Yuraimi Piz Ramos
Departamento de Endocrinología Pediátrica. Instituto Nacional de Endocrinología
Cómo citar
1.
Carvajal Martínez F, Piz Ramos Y. Riesgo aterogénico en el déficit de hormona de crecimiento: una mirada desde la infancia. cysa [Internet]. 1 de mayo de 2018 [citado 13 de noviembre de 2024];2(2):9-20. Disponible en: https://revistas.intec.edu.do/index.php/cisa/article/view/1177